04-01-2016, 11:37 PM
The abiraterone is a steroid compound CYP17 inhibitor, we want non-steroid inhibitors
Which I see we have some on the NBE list, oddly PM has a slight suppression of CYP17, how much I'm not sure. Though I'm pretty sure it's from Miroestrol, but because dexymirestrol is 10x stronger it hard to say.
Spiro is another example of a steroidal CYP 17 inhibitor.
Spirolactone increases the metabolic clearance of testosterone and inhibits androgen production
1. Prisant LM, Chin E. Gynecomastia and hyperten- sion. J Clin Hypertens (Greenwich) 2005;7:245-8.
2. Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gy- necomastia. Ann Intern Med 1977;87:398-403.
DOI:10.1503/cmaj.061286
Many medications have been associated with gynecomastia, including phytoestrogens, estrogens and drugs with estrogen-like properties (e.g., digitalis), inhibitors of testosterone synthesis or action (e.g., ketoconazole, metronidazole, cimetidine, alkylating agents, finasteride) and other agents with unknown mechanisms (isoniazid, methyldopa, tricyclic antidepressants, penicillamine, diazepam, omeprazole, calcium-channel blockers, angiotensin-converting-enzyme inhibitors, marijuana and heroin).
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800323/pdf/20070227s00013p620.pdf
Which I see we have some on the NBE list, oddly PM has a slight suppression of CYP17, how much I'm not sure. Though I'm pretty sure it's from Miroestrol, but because dexymirestrol is 10x stronger it hard to say.
Spiro is another example of a steroidal CYP 17 inhibitor.
Spirolactone increases the metabolic clearance of testosterone and inhibits androgen production
1. Prisant LM, Chin E. Gynecomastia and hyperten- sion. J Clin Hypertens (Greenwich) 2005;7:245-8.
2. Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gy- necomastia. Ann Intern Med 1977;87:398-403.
DOI:10.1503/cmaj.061286
Many medications have been associated with gynecomastia, including phytoestrogens, estrogens and drugs with estrogen-like properties (e.g., digitalis), inhibitors of testosterone synthesis or action (e.g., ketoconazole, metronidazole, cimetidine, alkylating agents, finasteride) and other agents with unknown mechanisms (isoniazid, methyldopa, tricyclic antidepressants, penicillamine, diazepam, omeprazole, calcium-channel blockers, angiotensin-converting-enzyme inhibitors, marijuana and heroin).
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800323/pdf/20070227s00013p620.pdf